Truist Financial analyst Les Sulewski maintained a Buy rating on Cormedix (CRMD – Research Report) today. The company’s shares closed yesterday at $5.41.
According to TipRanks, Sulewski is a 4-star analyst with an average return of 21.2% and a 77.78% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals, Cormedix, and Bausch Health Companies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cormedix with a $12.67 average price target, implying a 134.20% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.
CRMD market cap is currently $297.4M and has a P/E ratio of -5.82.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cormedix (CRMD) Company Description:
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Read More on CRMD:
